Beyond barriers: advances in vaginal drug delivery systems for women’s health
- 1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. Box 11562, Cairo, Egypt
- 2Ain Shams General Hospital, Cairo, Egypt
Abstract
The vaginal route has emerged as a promising alternative to conventional drug delivery approaches, offering advantages such as ease of administration, circumvention of hepatic first-pass metabolism, and the potential to achieve both localized and systemic therapeutic effects. Nevertheless, its broader clinical adoption is limited by physiological and biological barriers, including rapid mucus clearance, acidic pH, enzymatic degradation, and the complex dynamics of the vaginal microbiota, all of which compromise drug retention and absorption. This review analyzes more than 120 studies, including conventional dosage forms, nanocarrier-based systems, and advanced controlled-release platforms. Traditional dosage forms (creams, gels, suppositories, tablets, and films) remain widely used but are often limited by leakage, frequent dosing requirements, and poor patient adherence. To overcome these challenges, nanotechnology-based delivery systems such as lipid-based carriers, polymeric nanoparticles, and stimuli-responsive nanoplatforms have been developed, improving solubility, enhancing mucosal penetration, and enabling sustained or controlled drug release. Evidences from preclinical and clinical investigations show that these systems are effective in managing vaginal infections (e.g., bacterial vaginosis, vulvovaginal candidiasis), contraception, hormone replacement therapy, and localized cancer treatment. Furthermore, advanced platforms, including vaginal rings and bioadhesive formulations, provide prolonged drug release and improved patient compliance. By integrating findings across a large body of literature, this review highlights the transformative potential of nanocarrier-based and controlled-release systems in optimizing therapeutic efficacy and advancing women’s health care.
Related
- Advances in otic delivery: from anatomical barriers and disease challenges to nanocarriers, smart systems, and clinical translation
- Overcoming Biological Barriers: A Comprehensive Review of Advanced Melatonin Delivery Systems for Therapeutic Applications
- Advances in mucoadhesive drug delivery systems: Mechanistic insights, pharmacological performance, and translational pathways.
- Beyond Bioavailability: Lutein Delivery Systems and the Shift Toward Precision Nutrition
- In vivo CAR-T therapy: Delivery systems and beyond for addressing expression, persistence, and safety challenges
BibTeX
@article{ahmed2026beyond,
title = {{Beyond barriers: advances in vaginal drug delivery systems for women’s health}},
author = {Sadek Ahmed and Dina Mehana and Manal M. EL-Ashmoony},
journal = {Future Journal of Pharmaceutical Sciences},
year = {2026},
month = jul,
doi = {10.1186/s43094-026-00996-7},
url = {https://doi.org/10.1186/s43094-026-00996-7},
note = {CC BY},
}
RIS
TY - JOUR
TI - Beyond barriers: advances in vaginal drug delivery systems for women’s health
AU - Sadek Ahmed
AU - Dina Mehana
AU - Manal M. EL-Ashmoony
PY - 2026
DA - 2026/07/06
JO - Future Journal of Pharmaceutical Sciences
DO - 10.1186/s43094-026-00996-7
UR - https://doi.org/10.1186/s43094-026-00996-7
AB - The vaginal route has emerged as a promising alternative to conventional drug delivery approaches, offering advantages such as ease of administration, circumvention of hepatic first-pass metabolism, and the potential to achieve both localized and systemic therapeutic effects. Nevertheless, its broader clinical adoption is limited by physiological and biological barriers, including rapid mucus clearance, acidic pH, enzymatic degradation, and the complex dynamics of the vaginal microbiota, all of which compromise drug retention and absorption. This review analyzes more than 120 studies, including conventional dosage forms, nanocarrier-based systems, and advanced controlled-release platforms. Traditional dosage forms (creams, gels, suppositories, tablets, and films) remain widely used but are often limited by leakage, frequent dosing requirements, and poor patient adherence. To overcome these challenges, nanotechnology-based delivery systems such as lipid-based carriers, polymeric nanoparticles, and stimuli-responsive nanoplatforms have been developed, improving solubility, enhancing mucosal penetration, and enabling sustained or controlled drug release. Evidences from preclinical and clinical investigations show that these systems are effective in managing vaginal infections (e.g., bacterial vaginosis, vulvovaginal candidiasis), contraception, hormone replacement therapy, and localized cancer treatment. Furthermore, advanced platforms, including vaginal rings and bioadhesive formulations, provide prolonged drug release and improved patient compliance. By integrating findings across a large body of literature, this review highlights the transformative potential of nanocarrier-based and controlled-release systems in optimizing therapeutic efficacy and advancing women’s health care.
SN - 2314-7245
SN - 2314-7253
ER -